-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In the national medical insurance negotiation in 2021, the 700,000-injection Nosinagen Sodium dropped by 95%, and successfully entered the medical insurance catalog at a price of more than 30,000 yuan each; Daratumumab Injection, a drug with an annual treatment cost of more than 1 million yuan, was negotiated to less than 300,000 yua.
These news brought more hope to patients, and also gave some "prevention shots" to pharmaceutical companies who want to enter medical insuranc.
On August 8, Heilongjiang Province announced the list of drugs that companies applied for price reduction in July, including ripatinib, which has an annual cost of over one million yua.
Not only in Heilongjiang, but this drug also appeared in the list of drug price reductions released by the Yunnan Pharmacy Cente.
The list published by Heilongjiang shows that after the price adjustment of Ripatinib, the price of 30 tablets dropped from 33,266 yuan to 13,315 yuan, a drop of as much as 60.
According to the instructions for use of 3 tablets per day, this also means that the annual treatment cost of the corresponding patients will be reduced to less than 500,000 yuan, and only 479,000 yua.
Ripatinib is mainly used to treat adult patients with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more kinase inhibitors including imatini.
GIST is a gastrointestinal tumor with a very high incidence and recurrence rat.
There are about 30,000 newly diagnosed patients in China every yea.
At present, the majority of patients still face unmet clinical treatment need.
The developer of Ripatinib is Deciphera, and its product will receive priority review from China’s CDE in 2020, and will enter China through the Boao Lecheng Medical Pilot Zone in Haina.
And in March of the following year, it was officially approved for listing in Chin.
Zai Lab and Deciphera reached a cooperation in 2019, authorizing the introduction of the exclusive development and commercialization rights of the drug in Greater Chin.
Behind Zai Lab's aggressive price cut, industry analysts believe that it may be preparing for medical insuranc.
"Judging from the price standards for selected drugs in medical insurance negotiations over the years, it is unlikely that the annual treatment cost will exceed 500,000 to enter the negotiation, so it is necessary to pass this threshol.
" The cost of treatment will be controlled within 300,000 yuan, and the innovation, fairness, and effectiveness of the drug also need to be considere.
Therefore, whether Ripatinib can enter the new round of medical insurance needs to wait and se.
In addition to Zai Lab's Ripatinib, the list of drug price reductions released by Heilongjiang this time includes Pfizer's Palbociclib Capsules, AbbVie's Veneclaide Tablets, and Boehringer Ingelheim's Belintoo for Injectio.
Monoclonal antibody, levosimendan injection of Qilu Pharmaceutical, polyethylene glycol recombinant human growth hormone injection of Changchun Jinsai, docetaxel injection of Meida Konkale and other heavy varieties of domestic and foreign pharmaceutical companies Corresponding price adjustments have also been mad.
Among them, the price of Boehringer Ingelheim's leukemia drug belintoumumab for injection per box of 35μg × 1 bottle dropped from 12,900 yuan to 9,615 yuan, a price reduction of more than 25%; Qilu Pharmaceutical's levosimendan injection 5ml : 15mg dropped from 2,300 yuan per bottle to 1,737 yuan per bottle, a decrease of 25.
For pharmaceutical companies, the entry of products into the medical insurance catalog can ensure the stable growth of the in-hospital marke.
In recent years, it is not uncommon for both multinational and local pharmaceutical companies to significantly cut prices for medical insuranc.
With the normalization of centralized procurement and the advancement of medical insurance negotiations, the industry expects that drug prices will become a major trend, and the era of inflated drug prices in the past will be gone foreve.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
These news brought more hope to patients, and also gave some "prevention shots" to pharmaceutical companies who want to enter medical insuranc.
On August 8, Heilongjiang Province announced the list of drugs that companies applied for price reduction in July, including ripatinib, which has an annual cost of over one million yua.
Not only in Heilongjiang, but this drug also appeared in the list of drug price reductions released by the Yunnan Pharmacy Cente.
The list published by Heilongjiang shows that after the price adjustment of Ripatinib, the price of 30 tablets dropped from 33,266 yuan to 13,315 yuan, a drop of as much as 60.
According to the instructions for use of 3 tablets per day, this also means that the annual treatment cost of the corresponding patients will be reduced to less than 500,000 yuan, and only 479,000 yua.
Ripatinib is mainly used to treat adult patients with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more kinase inhibitors including imatini.
GIST is a gastrointestinal tumor with a very high incidence and recurrence rat.
There are about 30,000 newly diagnosed patients in China every yea.
At present, the majority of patients still face unmet clinical treatment need.
The developer of Ripatinib is Deciphera, and its product will receive priority review from China’s CDE in 2020, and will enter China through the Boao Lecheng Medical Pilot Zone in Haina.
And in March of the following year, it was officially approved for listing in Chin.
Zai Lab and Deciphera reached a cooperation in 2019, authorizing the introduction of the exclusive development and commercialization rights of the drug in Greater Chin.
Behind Zai Lab's aggressive price cut, industry analysts believe that it may be preparing for medical insuranc.
"Judging from the price standards for selected drugs in medical insurance negotiations over the years, it is unlikely that the annual treatment cost will exceed 500,000 to enter the negotiation, so it is necessary to pass this threshol.
" The cost of treatment will be controlled within 300,000 yuan, and the innovation, fairness, and effectiveness of the drug also need to be considere.
Therefore, whether Ripatinib can enter the new round of medical insurance needs to wait and se.
In addition to Zai Lab's Ripatinib, the list of drug price reductions released by Heilongjiang this time includes Pfizer's Palbociclib Capsules, AbbVie's Veneclaide Tablets, and Boehringer Ingelheim's Belintoo for Injectio.
Monoclonal antibody, levosimendan injection of Qilu Pharmaceutical, polyethylene glycol recombinant human growth hormone injection of Changchun Jinsai, docetaxel injection of Meida Konkale and other heavy varieties of domestic and foreign pharmaceutical companies Corresponding price adjustments have also been mad.
Among them, the price of Boehringer Ingelheim's leukemia drug belintoumumab for injection per box of 35μg × 1 bottle dropped from 12,900 yuan to 9,615 yuan, a price reduction of more than 25%; Qilu Pharmaceutical's levosimendan injection 5ml : 15mg dropped from 2,300 yuan per bottle to 1,737 yuan per bottle, a decrease of 25.
For pharmaceutical companies, the entry of products into the medical insurance catalog can ensure the stable growth of the in-hospital marke.
In recent years, it is not uncommon for both multinational and local pharmaceutical companies to significantly cut prices for medical insuranc.
With the normalization of centralized procurement and the advancement of medical insurance negotiations, the industry expects that drug prices will become a major trend, and the era of inflated drug prices in the past will be gone foreve.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
